dc.contributor.author | Smithen, Deborah A. | en_US |
dc.contributor.author | Forrester, A. Michael | en_US |
dc.contributor.author | Corkery, Dale P. | en_US |
dc.contributor.author | Dellaire, Graham | en_US |
dc.contributor.author | Colpitts, Julie | en_US |
dc.contributor.author | McFarland, Sherri A. | en_US |
dc.contributor.author | Berman, Jason N. | en_US |
dc.contributor.author | Thompson, Alison | en_US |
dc.date.accessioned | 2013-08-12T17:55:00Z | |
dc.date.available | 2013-08-12T17:55:00Z | |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | Smithen, Deborah A., A. Michael Forrester, Dale P. Corkery, Graham Dellaire, et al. 2013. "Investigations regarding the utility of prodigiosenes to treat leukemia." Organic & Biomolecular Chemistry 11(1): 62-68. | en_US |
dc.identifier.issn | 1477-0520 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1039/c2ob26535d | en_US |
dc.identifier.uri | http://hdl.handle.net/10222/30728 | |
dc.description.abstract | Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer
activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed
promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer
cell line panel. Further in vivo studies of these compounds using the zebrafish model showed
persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells. | en_US |
dc.relation.ispartof | Organic & Biomolecular Chemistry | en_US |
dc.title | Investigations regarding the utility of prodigiosenes to treat leukemia | en_US |
dc.type | article | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 62 | en_US |